Cite
9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
MLA
Gerhard, Hartmann, Elena, et al. “9p24.1 Alterations and Programmed Cell Death 1 Ligand 1 Expression in Early Stage Unfavourable Classical Hodgkin Lymphoma: An Analysis from the German Hodgkin Study Group NIVAHL Trial.” British Journal of Haematology, vol. 196, no. 1, Jan. 2022, pp. 116–26. EBSCOhost, https://doi.org/10.1111/bjh.17793.
APA
Gerhard, H. E., Goergen, H., Bröckelmann, P. J., Mottok, A., Steinmüller, T., Grund, J., Zamò, A., Ben, N. S., Sasse, S., Borchmann, S., Fuchs, M., Borchmann, P., Reinke, S., Engert, A., Veldman, J., Diepstra, A., Klapper, W., & Rosenwald, A. (2022). 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial. British Journal of Haematology, 196(1), 116–126. https://doi.org/10.1111/bjh.17793
Chicago
Gerhard, Hartmann, Elena, Helen Goergen, Paul J. Bröckelmann, Anja Mottok, Tabea Steinmüller, Johanna Grund, Alberto Zamò, et al. 2022. “9p24.1 Alterations and Programmed Cell Death 1 Ligand 1 Expression in Early Stage Unfavourable Classical Hodgkin Lymphoma: An Analysis from the German Hodgkin Study Group NIVAHL Trial.” British Journal of Haematology 196 (1): 116–26. doi:10.1111/bjh.17793.